@article{MTMT:34784503,
	title = {Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials},
	url = {https://m2.mtmt.hu/api/publication/34784503},
	author = {Wu, X. and Wang, S. and Xue, T. and Tan, X. and Li, J. and Chen, Z. and Wang, Z.},
	doi = {10.3389/fneur.2024.1295770},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34784503},
	issn = {1664-2295},
	abstract = {Background: Currently, disease-modifying therapies (DMTs) for progressive multiple sclerosis (PMS) are widely used in clinical practice. At the same time, there are a variety of drug options for DMTs, but the effect of the drugs that can better relieve symptoms and improve the prognosis are still inconclusive. Objectives: This systematic review aimed to evaluate the efficacy and safety of DMTs for PMS and to identify the best among these drugs. Methods: MEDLINE, EMBASE, the Cochrane Library, and clinicaltrials.gov were systematically searched to identify relevant studies published before 30 January, 2023. We assessed the certainty of the evidence using the confidence in the network meta-analysis (CINeMA) framework. We estimated the summary risk ratio (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes with 95% credible intervals (CrIs). Results: We included 18 randomized controlled trials (RCTs) involving 9,234 patients in the study. DMT can effectively control the disease progression of MS. Among them, mitoxantrone, siponimod, and ocrelizumab are superior to other drug options in delaying disease progression (high certainty). Mitoxantrone was the best (with high certainty) for mitigating deterioration (progression of disability). Ocrelizumab performed best on the pre- and post-treatment Timed 25-Foot Walk test (T25FW; low certainty), as did all other agents (RR range: 1.12–1.05). In the 9-Hole Peg Test (9HPT), natalizumab performed the best (high certainty), as did all other agents (RR range: 1.59–1.09). In terms of imaging, IFN-beta-1b performed better on the new T2 hypointense lesion on contrast, before and after treatment (high certainty), while siponimod performed best on the change from baseline in the total volume of lesions on T2-weighted image contrast before and after treatment (high certainty), and sWASO had the highest area under the curve (SUCRA) value (100%). In terms of adverse events (AEs), rituximab (RR 1.01), and laquinimod (RR 1.02) were more effective than the placebo (high certainty). In terms of serious adverse events (SAEs), natalizumab (RR 1.09), and ocrelizumab (RR 1.07) were safer than placebo (high certainty). Conclusion: DMTs can effectively control disease progression and reduce disease deterioration during the treatment of PMS. Systematic review registration: https://inplasy.com/?s=202320071, identifier: 202320071. Copyright © 2024 Wu, Wang, Xue, Tan, Li, Chen and Wang.},
	keywords = {Male; review; human; confidence interval; nuclear magnetic resonance imaging; outcome assessment; drug efficacy; disease exacerbation; area under the curve; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS; rituximab; rituximab; systematic review; meta analysis; mitoxantrone; Cochrane Library; glatiramer; beta1a interferon; Data extraction; randomized controlled trial (topic); Expanded Disability Status Scale; ocrelizumab; ocrelizumab; fingolimod; laquinimod; natalizumab; natalizumab; Markov Chain Monte Carlo method; dimethyl fumarate; DISEASE-MODIFYING THERAPY; siponimod; progressive multiple sclerosis; adverse event; dispersity; Research Diagnostic Criteria; Nine Hole Peg Test; Randomized controlled; beta1b interferon; biologic factors and agents acting on the immune system},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34781460,
	title = {Therapeutic inertia in the management of neuromyelitis optica spectrum disorder},
	url = {https://m2.mtmt.hu/api/publication/34781460},
	author = {Cobo-Calvo, Á. and Gómez-Ballesteros, R. and Orviz, A. and Díaz, Sánchez M. and Boyero, S. and Aguado-Valcarcel, M. and Sepúlveda, M. and Rebollo, P. and López-Laiz, P. and Maurino, J. and Téllez, Lara N.},
	doi = {10.3389/fneur.2024.1341473},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34781460},
	issn = {1664-2295},
	abstract = {Introduction and objective: Limited information is available on how neurologists make therapeutic decisions in neuromyelitis optica spectrum disorder (NMOSD), especially when new treatments with different mechanisms of action, administration, and safety profile are being approved. Decision-making can be complex under this uncertainty and may lead to therapeutic inertia (TI), which refers to lack of treatment initiation or intensification when therapeutic goals are not met. The study aim was to assess neurologists’ TI in NMOSD. Methods: An online, cross-sectional study was conducted in collaboration with the Spanish Society of Neurology. Neurologists answered a survey composed of demographic characteristics, professional background, and behavioral traits. TI was defined as the lack of initiation or intensification with high-efficacy treatments when there is evidence of disease activity and was assessed through five NMOSD aquaporin-4 positive (AQP4+) simulated case scenarios. A multivariate logistic regression analysis was used to determine the association between neurologists’ characteristics and TI. Results: A total of 78 neurologists were included (median interquartile range [IQR] age: 36.0 [29.0–46.0] years, 55.1% male, median [IQR] experience managing demyelinating conditions was 5.2 [3.0–11.1] years). The majority of participants were general neurologists (59.0%) attending a median (IQR) of 5.0 NMOSD patients (3.0–12.0) annually. Thirty participants (38.5%) were classified as having TI. Working in a low complexity hospital and giving high importance to patient’s tolerability/safety when choosing a treatment were predictors of TI. Conclusion: TI is a common phenomenon among neurologists managing NMOSD AQP4+. Identifying TI and implementing specific intervention strategies may be critical to improving therapeutic decisions and patient care. Copyright © 2024 Cobo-Calvo, Gómez-Ballesteros, Orviz, Díaz Sánchez, Boyero, Aguado-Valcarcel, Sepúlveda, Rebollo, López-Laiz, Maurino and Téllez Lara.},
	keywords = {Adult; Female; Male; PREVALENCE; INFECTION; ARTICLE; KNOWLEDGE; PERCEPTION; human; questionnaire; physician; human experiment; outcome assessment; scoring system; disease activity; decision making; patient care; cross-sectional study; Aquaporin 4; multivariate logistic regression analysis; demyelinating disease; neuromyelitis optica; Demographics; neurologist; Likert scale; SHARED DECISION-MAKING; myelooptic neuropathy; therapeutic inertia; therapeutic error; experiential knowledge; THEORETICAL KNOWLEDGE; Severe disease; high-efficacy treatments; Evidence Based Practice Attitude Scale; General Risk Propensity Scale; interactional knowledge; Jefferson Scale of Physician Empathy; Provider Decision Process Assessment Instrument; Reasons for Treatment Selection Questionnaire; Regret Intensity Scale; situational knowledge},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34780684,
	title = {Cilostazol-based dual antiplatelet treatment in ischemic stroke or transient ischemic attack patients with asymptomatic carotid artery disease: a propensity score matching analysis},
	url = {https://m2.mtmt.hu/api/publication/34780684},
	author = {Thiraworawong, T. and Pathonsmith, C.},
	doi = {10.3389/fneur.2024.1362124},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34780684},
	issn = {1664-2295},
	abstract = {Background: The optimal treatment for asymptomatic atherosclerotic carotid artery disease remains controversial. Data on the efficacy of antiplatelet agents and stroke outcomes are limited. This study aimed to examine the efficacy and safety of cilostazol-based dual antiplatelet therapy in patients with ischemic stroke or transient ischemic attack and asymptomatic carotid artery disease. Methods: This retrospective cohort study was conducted in a tertiary-care setting and included baseline characteristics and clinical outcomes of participants. The study included patients who had experienced first-ever ischemic stroke or transient ischemic attack and asymptomatic atherosclerotic carotid artery stenosis, with a minimum follow-up period of 1 year. Asymptomatic carotid artery stenosis refers to stenosis in patients without neurological symptoms referable to the carotid arteries. Propensity scores were estimated using a logistic regression model based on participants’ baseline characteristics. The efficacy outcome was the composite outcome of recurrent ischemic events and vascular-related death in patients with ischemic stroke or transient ischemic attack and asymptomatic carotid artery stenosis. The safety outcome was the occurrence of hemorrhagic complications such as intracranial hemorrhages or extracranial hemorrhages. The effectiveness of dual therapy compared to monotherapy was evaluated at various time points following the initiation of antiplatelet treatment. Results: This study included 516 patients with a 1-year follow-up period. At 1 year, composite events occurred in 10 (6.3%) patients in the dual antiplatelet group compared with 12 (7.6%) in the single antiplatelet group (HR, 0.74; 95% CI, 0.61–0.90; p = 0.024). Extracranial hemorrhage occurred in 12 (7.6%) patients in the dual antiplatelet group compared with nine (5.7%) in the single antiplatelet group (HR, 1.35; 95% CI, 1.13–1.48; p = 0.017). No intracranial hemorrhages were observed in this cohort. Conclusion: Patients with asymptomatic carotid artery stenosis who received cilostazol-based dual antiplatelet therapy had a lower risk of composite events but a higher risk of minor extracranial hemorrhage than those who received a single antiplatelet agent. Copyright © 2024 Thiraworawong and Pathonsmith.},
	keywords = {Blood Pressure; Aged; Adult; Female; Male; ARTICLE; neurologic disease; human; diabetes mellitus; major clinical study; cohort analysis; retrospective study; outcome assessment; hemoglobin A1c; low density lipoprotein cholesterol; transient ischemic attack; ischemic stroke; ischemic stroke; Carotid stenosis; Carotid stenosis; Clopidogrel; carotid artery disease; loading drug dose; treatment duration; Asymptomatic; National Institutes of Health Stroke Scale; cilostazol; cilostazol; Dual antiplatelet therapy; ABCD2 score; Dual antiplatelet},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34779375,
	title = {Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy},
	url = {https://m2.mtmt.hu/api/publication/34779375},
	author = {Schaefer, J.H. and Lieschke, F. and Urban, H. and Bohmann, F.O. and Gatzke, F. and Miesbach, W.},
	doi = {10.3389/fneur.2024.1361751},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34779375},
	issn = {1664-2295},
	abstract = {Background: The clinical course of ischemic and hemorrhagic strokes can be influenced by the coagulation status of individual patients. The prior use of antiplatelet therapy (APT) such as acetylsalicylic acid (ASA) or P2Y12-antagonists has been inconsistently described as possibly increasing the risk of hemorrhagic transformation or expansion. Since clinical studies describing prior use of antiplatelet medication are overwhelmingly lacking specific functional tests, we aimed to implement testing in routine stroke care. Methods: We used fluorescence-activated cell sorting (FACS) with antibodies against CD61 for thrombocyte identification and CD62p or platelet activation complex-1 (PAC-1) to determine platelet activation. Aggregometry and automated platelet functioning analyzer (PFA-200) were employed to test thrombocyte reactivity. FACS and aggregometry samples were stimulated in vitro with arachidonic acid (AA) and adenosine diphosphate (ADP) to measure increase in CD62p-/PAC-1-expression or aggregation, respectively. Results: Between February and July 2023, 20 blood samples (n = 11 ischemic strokes; n = 7 hemorrhagic strokes; n = 2 controls) were acquired and analyzed within 24 h of symptom onset. N = 11 patients had taken ASA, n = 8 patients no APT and n = 1 ASA+clopidogrel. ASA intake compared to no APT was associated with lower CD62p expression after stimulation with AA on FACS analysis (median 15.8% [interquartile range {IQR} 12.6–37.2%] vs. 40.1% [IQR 20.3–56.3%]; p = 0.020), lower platelet aggregation (9.0% [IQR 7.0–12.0%] vs. 88.5% [IQR 11.8–92.0%]; p = 0.015) and longer time to plug formation with PFA-200 (248.0 s [IQR 157.0–297] vs. 121.5 s [IQR 99.8–174.3]; p = 0.027). Significant correlations were noted between AA-induced CD62p expression and aggregometry analysis (n = 18; ρ = 0.714; p < 0.001) as well as a negative correlation between CD62p increase and PFA clot formation time (n = 18; ρ = −0.613; p = 0.007). Sensitivity for ASA intake was highest for PFA (81.8% for values ≥155.5 s). The combination of ASA + clopidogrel also affected ADP-induced CD62p and PAC-1 expression. Conclusion: In the clinical setting it is feasible to use differentiated platelet analytics to determine alterations caused by antiplatelet therapy. Among the tests under investigation, PFA-200 showed the highest sensitivity for the intake of ASA in stroke patients. FACS analysis on the other hand might be able to provide a more nuanced approach to altered platelet reactivity. Copyright © 2024 Schaefer, Lieschke, Urban, Bohmann, Gatzke and Miesbach.},
	keywords = {Adult; Female; Middle Aged; Male; PLATELETS; ARTICLE; human; Measurement; comparative study; brain hemorrhage; clinical article; in vitro study; prospective study; protein expression; Arachidonic Acid; blood sampling; ischemic stroke; ischemic stroke; ACUTE STROKE; receiver operating characteristic; feasibility study; thrombocyte aggregation; thrombocyte activation; PADGEM protein; function test; adenosine diphosphate; fluorescence activated cell sorting; vein puncture; Rankin scale; FACS; PLATELET REACTIVITY; HEMORRHAGIC STROKE; clot formation time; Dual antiplatelet therapy; acetylsalicylic acid plus clopidogrel; beta3 integrin; Thrombocytes; aggregometry; aggregometry; platelet function test; platelet functioning analyzer},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34768699,
	title = {Long-term follow-up of an attenuated presentation of NAXE-related disease, a potentially actionable neurometabolic disease: a case report},
	url = {https://m2.mtmt.hu/api/publication/34768699},
	author = {Almudhry, M. and Prasad, C. and Rupar, C.A. and Tay, K.Y. and Prasad, A.N.},
	doi = {10.3389/fneur.2024.1204848},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34768699},
	issn = {1664-2295},
	abstract = {Background: Early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy (PEBEL-1) is an autosomal recessive disorder whereby a fluctuating clinical course is exacerbated by febrile illnesses. Pathogenic NAD(P)HX epimerase (NAXE) gene mutations underpin this disorder. This mutation damages the metabolite repair system involved in regenerating crucial redox carriers. Longer survival has rarely been reported in this potentially actionable entity. Objectives: This case study aims to report a milder phenotype of a patient with NAXE gene mutation and his longitudinal follow-up of more than 20 years. Case report: A 24-year-old man first became symptomatic in infancy with frequent initial neurological decompensations in the setting of infections with subsequent clinical improvement followed by stability with residual cerebellar dysfunction. Clinical features noted over the years include chronic ataxia, nystagmus, ptosis, mild spasticity of lower limbs, and neuropsychiatric symptoms. Cerebellar and spinal cord atrophy were noted in cranial and spinal MR imaging. Biallelic homozygous variants in the NAXE gene (c.733 A>C) were identified on whole exome sequencing. Symptom management included the initiation of a mitochondrial cocktail with carnitine, coenzyme Q, and thiamine. Subsequently, niacin (Vitamin B3), which is involved in the cellular biosynthesis of NAD+, was added, given its potentially beneficial therapeutic impact. Conclusion: A missense homozygous variant in the NAXE gene is described in this patient with a milder clinical phenotype of the disease. Supplementation with niacin in addition to a mitochondrial cocktail presents a potential supportive therapeutic option to reduce disease progression. Copyright © 2024 Almudhry, Prasad, Rupar, Tay and Prasad.},
	keywords = {Adult; Male; GENE; NICOTINAMIDE; ARTICLE; ALLELE; neurologic disease; human; gene mutation; clinical feature; biosynthesis; nuclear magnetic resonance imaging; case report; clinical article; cognition; CEREBELLUM; fatigue; Gene Expression; Young Adult; Gait; Cesarean Section; cerebrospinal fluid; confusion; ATAXIA; thiamine; citalopram; follow up; inborn error of metabolism; mental disease; disorders of mitochondrial functions; motor performance; anxiety disorder; carnitine; mental health; motor dysfunction; lactate blood level; nicotinamide adenine dinucleotide; missense mutation; computer model; Vitamin B Complex; Niacin; nicotinic acid; ear infection; riboflavin; metabolic disorder; cerebellar ataxia; ophthalmoplegia; spasticity; obsessive compulsive disorder; language ability; scoliosis; pyruvate dehydrogenase; lethargy; Whole exome sequencing; NEUROPSYCHOLOGICAL ASSESSMENT; cerebellum disease; ubiquinone; strabismus; blood biochemistry; kyphoscoliosis; ptosis (eyelid); FMR1 gene; hearing acuity; physical disease by anatomical structure; NPC1 gene; NAD(P)HX epimerase; PEBEL1; NAXE gene; NAXE gene; pathologic nystagmus; lumbar scoliosis; NAXE related disease; NAXE related disease; NPC2 gene},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34764525,
	title = {Biomarkers and Tourette syndrome: a systematic review and meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/34764525},
	author = {Jiang, Y. and Li, Y. and Chen, X. and Zhai, R. and Peng, Y. and Tai, R. and Zhou, C. and Wang, J.},
	doi = {10.3389/fneur.2024.1262057},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34764525},
	issn = {1664-2295},
	abstract = {Objective: This research aims to investigate whether peripheral biomarkers might differentiate individuals with Tourette syndrome (TS) from those without the condition. Methods: A broad range of databases was searched through November 2022. This study employed a systematic literature review and subsequent meta-analysis of case-control studies that assessed the aberration of biomarkers of patients with TS and controls. Results: A total of 81 studies were identified, out of which 60 met the eligibility criteria for inclusion in the meta-analysis. Following a meticulous screening procedure to determine the feasibility of incorporating case–control studies into the meta-analysis, 13 comparisons were statistically significant [CD3+ T cell, CD4+ T cell, CD4+ T cell to CD8+ T cell ratio, NK-cell, anti-streptolysin O antibodies, anti-DNase antibodies, glutamic acid (Glu), aspartic acid (Asp), ferritin (Fe), zinc (Zn), lead (Pb), vitamin D, and brain-derived neurotrophic factor (BDNF)]. Publication bias was found for anti-streptolysin O antibodies. Suggestive associations were evidenced for norsalsolinol (NSAL), neuron-specific enolase (NSE), and S100B. Conclusion: In this study, we present empirical evidence substantiating the link between several peripheral biomarkers and the early diagnosis of TS. Larger and more standardized studies are necessary to replicate the observed results, elucidate the specificity of the biomarkers for TS, and evaluate their precision for use in clinical settings. Copyright © 2024 Jiang, Li, Chen, Zhai, Peng, Tai, Zhou and Wang.},
	keywords = {Dopamine; CHILDREN; COMPLEMENT; SEROTONIN; ANTIBODY; cytokine; review; human; trace element; Child; Biomarkers; statistical analysis; ZINC; diagnosis; IRON; biological marker; immune system; lead; glutamic acid; Meta-analysis; unclassified drug; immunocompetent cell; protein S100B; VITAMIN; systematic review; meta analysis; CD8+ T lymphocyte; aspartic acid; brain derived neurotrophic factor; vitamin D; natural killer cell; CD4+ T lymphocyte; neurotransmitter; noradrenalin; CD4 CD8 ratio; hypothalamus hypophysis adrenal system; Gilles de la Tourette syndrome; Tourette syndrome; Data extraction; CD3+ T lymphocyte; neuron specific enolase; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; Newcastle-Ottawa scale; trace amine associated receptor; antistreptolysin; natural products and their synthetic derivatives; norsalsolinol},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34760066,
	title = {Harmonizing multisite data with the ComBat method for enhanced Parkinson’s disease diagnosis via DAT-SPECT},
	url = {https://m2.mtmt.hu/api/publication/34760066},
	author = {Wakasugi, N. and Takano, H. and Abe, M. and Sawamoto, N. and Murai, T. and Mizuno, T. and Matsuoka, T. and Yamakuni, R. and Yabe, H. and Matsuda, H. and Hanakawa, T.},
	doi = {10.3389/fneur.2024.1306546},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34760066},
	issn = {1664-2295},
	abstract = {Background: Dopamine transporter single-photon emission computed tomography (DAT-SPECT) is a crucial tool for evaluating patients with Parkinson’s disease (PD). However, its implication is limited by inter-site variability in large multisite clinical trials. To overcome the limitation, a conventional prospective correction method employs linear regression with phantom scanning, which is effective yet available only in a prospective manner. An alternative, although relatively underexplored, involves retrospective modeling using a statistical method known as “combatting batch effects when combining batches of gene expression microarray data” (ComBat). Methods: We analyzed DAT-SPECT-specific binding ratios (SBRs) derived from 72 healthy older adults and 81 patients with PD registered in four clinical sites. We applied both the prospective correction and the retrospective ComBat correction to the original SBRs. Next, we compared the performance of the original and two corrected SBRs to differentiate the PD patients from the healthy controls. Diagnostic accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The original SBRs were 6.13 ± 1.54 (mean ± standard deviation) and 2.03 ± 1.41 in the control and PD groups, respectively. After the prospective correction, the mean SBRs were 6.52 ± 1.06 and 2.40 ± 0.99 in the control and PD groups, respectively. After the retrospective ComBat correction, the SBRs were 5.25 ± 0.89 and 2.01 ± 0.73 in the control and PD groups, respectively, resulting in substantial changes in mean values with fewer variances. The original SBRs demonstrated fair performance in differentiating PD from controls (Hedges’s g = 2.76; AUC-ROC = 0.936). Both correction methods improved discrimination performance. The ComBat-corrected SBR demonstrated comparable performance (g = 3.99 and AUC-ROC = 0.987) to the prospectively corrected SBR (g = 4.32 and AUC-ROC = 0.992) for discrimination. Conclusion: Although we confirmed that SBRs fairly discriminated PD from healthy older adults without any correction, the correction methods improved their discrimination performance in a multisite setting. Our results support the utility of harmonization methods with ComBat for consolidating SBR-based diagnosis or stratification of PD in multisite studies. Nonetheless, given the substantial changes in the mean values of ComBat-corrected SBRs, caution is advised when interpreting them. Copyright © 2024 Wakasugi, Takano, Abe, Sawamoto, Murai, Mizuno, Matsuoka, Yamakuni, Yabe, Matsuda, Hanakawa and Parkinson’s and Alzheimer’s disease Dimensional Neuroimaging Initiative (PADNI).},
	keywords = {Aged; Female; Male; DOPAMINE TRANSPORTER; MAJOR DEPRESSION; ARTICLE; human; major clinical study; controlled study; cohort analysis; retrospective study; area under the curve; Parkinson's disease; Parkinson disease; neuroimaging; Alzheimer disease; correlation coefficient; receiver operating characteristic; daily life activity; diagnostic test accuracy study; Harmonization; clinical dementia rating scale; trail making test; NEUROPSYCHOLOGICAL ASSESSMENT; Montreal Cognitive Assessment; dopamine transporter single-photon emission computed tomography; single photon emission computed tomography-computed tomography; MDS-Unified Parkinson Disease Rating Scale; multicenter cohort study; combatting batch effects when combining batches of gene expression microarray data},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34758263,
	title = {Risk factors for intracerebral hemorrhage in small-vessel disease and non-small-vessel disease etiologies-an observational proof-of-concept study},
	url = {https://m2.mtmt.hu/api/publication/34758263},
	author = {Arndt, Philipp and Chahem, Christian and Luchtmann, Michael and Kuschel, Jan-Niklas and Behme, Daniel and Pfister, Malte and Neumann, Jens and Goertler, Michael and Doerner, Marc and Pawlitzki, Marc and Jansen, Robin and Meuth, Sven G. and Vielhaber, Stefan and Henneicke, Solveig and Schreiber, Stefanie},
	doi = {10.3389/fneur.2024.1322442},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34758263},
	issn = {1664-2295},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34756282,
	title = {Habituation disorders in auditory middle latency response of persistent postural-perceptual dizziness patients},
	url = {https://m2.mtmt.hu/api/publication/34756282},
	author = {Murofushi, T. and Goto, F. and Ushio, M.},
	doi = {10.3389/fneur.2024.1366420},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34756282},
	issn = {1664-2295},
	year = {2024},
	eissn = {1664-2295}
}

@article{MTMT:34751286,
	title = {Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain},
	url = {https://m2.mtmt.hu/api/publication/34751286},
	author = {Goicochea, Briceño H. and Higueras, Y. and Ruiz, Pérez I. and García, Domínguez J.M. and Cuello, J.P. and Meldaña, Rivera A. and Martínez, Ginés M.L.},
	doi = {10.3389/fneur.2024.1360032},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {15},
	unique-id = {34751286},
	issn = {1664-2295},
	year = {2024},
	eissn = {1664-2295}
}